Julian Hung's questions to ACADIA Pharmaceuticals Inc (ACAD) leadership • Q4 2024
Question
Julian Hung, on for Paul Mattias, asked about the reasons for the wider-than-usual 2025 guidance range for NUPLAZID and questioned the company's confidence in securing favorable reimbursement for DAYBUE in the EU.
Answer
CFO Mark Schneyer attributed the wider NUPLAZID guidance to uncertainty surrounding the new Medicare Part D redesign, which could create both positive and negative volume impacts. CCO Tom Garner expressed high confidence in the EU launch of DAYBUE, citing strong inbound interest from caregivers, the build-out of an experienced team, and a growing body of real-world data to support reimbursement discussions.